Disparities in colorectal cancer in African-Americans vs Whites: Before and after diagnosis

Dimou, Anastasios; Syrigos, Kostas; Saif, Muhammad Wasif

doi:10.3748/wjg.15.3734

Cited by 122 publications

(106 citation statements)

References 91 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The highest mortality rates occur in Central and Eastern European countries, and the lowest (15). In China in 2009, colorectal cancer incidence and mortality rates were higher than the world averages: Rates were than lower that observed in Japan, Singapore and South Korea, but higher than that of countries such as Iran, Laos and India (16,17). In the present study, it was demonstrated that naphthazarin significantly decreased cell viability, increased cytotoxicity and induced cellular and nuclear apoptosis of SW480 cells in a dose-dependent manner.…”

Section: Discussionmentioning

confidence: 98%

Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway

Chen

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Colorectal cancer is the most common gastrointestinal cancer in the USA. Naphthazarin, one of the naturally available 1,4-naphthoquinone derivatives, is a natural bioactive molecule that exhibits an antitumor effect. To the best of our knowledge, this is the first study to investigate the anticancer effect of naphthazarin on cell proliferation and apoptosis in human SW480 colorectal cancer cells. In the present study, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and lactate dehydrogenase assays were performed to assess the effect of napthazarin on cell proliferation and cytotoxicity of SW430 cells, respectively. In addition, an Annexin V-fluorescein isothiocyanate/propidium iodide apoptosis assay and 4' ,6-diamidino-2-phenylindole staining were used to analyze cell and nuclei apoptosis of SW480 cells, respectively, following treatment with naphthazarin. Poly (ADP-ribose) polymerase (PARP), B-cell lymphoma 2 (Bcl-2) and B-cell associated X protein (Bax) protein expression was analyzed by western blot. Furthermore, caspase-3 activation was analyzed using a commercial kit. The results revealed that naphthazarin exhibited cell growth inhibition, an increase in cytotoxicity and apoptosis induction in SW480 cells, which was associated with activation of the Bax/Bcl-2 signaling pathway and cleaved caspase-3 activation. However, no significant differences in PARP expression were identified following treatment with naphthazarin in SW480 cells. Taken together, these results suggest that naphthazarin decreased cell viability and induced apoptosis of SW480 cells, indicating that naphthazarin may present a potential therapeutic agent for human colorectal cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 98%

Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway

Chen

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…[15][16][17][18][19] Data from both the breast and colorectal cancer literature have demonstrated that certain racial groups often decline chemotherapy treatment. [20][21][22][23][24][25][26] Factors influencing provider and patient preferences remains poorly understood and continue to be an active area of investigation.…”

Section: Discussionmentioning

confidence: 99%

A Multi-institutional Study of Pancreatic Cancer in Harris County, Texas: Race Predicts Treatment and Survival

et al. 2012

View full text Add to dashboard Cite

show abstract

“…5,7,14 Compared with white patients, cancer surveillance is lower and cancerrelated mortality is higher among African American patients. 5,9,10 Unequal access to health care services has been attributed as a contributing factor for racial disparities in care. 3,15,16 The VA health care system provides a good context in which to study racial disparities because of standard VA eligibility criteria and narrow distribution of family income among VA patients, making access issues among individuals of different races narrower than for non-VA systems.…”

Section: Introductionmentioning

confidence: 99%

“…2 In nonfederal US health care systems, racial differences in CRC diagnosis, treatment, and mortality have been documented. [3][4][5][6][7][8][9][10][11][12][13] For example, fewer African Americans receive adjuvant chemotherapy for CRC compared with whites. 5,7,14 Compared with white patients, cancer surveillance is lower and cancerrelated mortality is higher among African American patients.…”

Section: Introductionmentioning

confidence: 99%

“…[3][4][5][6][7][8][9][10][11][12][13] For example, fewer African Americans receive adjuvant chemotherapy for CRC compared with whites. 5,7,14 Compared with white patients, cancer surveillance is lower and cancerrelated mortality is higher among African American patients. 5,9,10 Unequal access to health care services has been attributed as a contributing factor for racial disparities in care.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Examining Potential Colorectal Cancer Care Disparities in the Veterans Affairs Health Care System

Zullig

Carpenter

Provenzale

et al. 2013

JCO

View full text Add to dashboard Cite

A B S T R A C T PurposeRacial disparities in cancer treatment and outcomes are a national problem. The nationwide Veterans Affairs (VA) health system seeks to provide equal access to quality care. However, the relationship between race and care quality for veterans with colorectal cancer (CRC) treated within the VA is poorly understood. We examined the association between race and receipt of National Comprehensive Cancer Network guideline-concordant CRC care. Patients and MethodsThis was an observational, retrospective medical record abstraction of patients with CRC treated in the VA. Two thousand twenty-two patients (white, n ϭ 1,712; African American, n ϭ 310) diagnosed with incident CRC between October 1, 2003, and March 31, 2006, from 128 VA medical centers, were included. We used multivariable logistic regression to examine associations between race and receipt of guideline-concordant care (computed tomography scan, preoperative carcinoembryonic antigen, clear surgical margins, medical oncology referral for stages II and III, fluorouracil-based adjuvant chemotherapy for stage III, and surveillance colonoscopy for stages I to III). Explanatory variables included demographic and disease characteristics. ResultsThere were no significant racial differences for receipt of guideline-concordant CRC care. Older age at diagnosis was associated with reduced odds of medical oncology referral and surveillance colonoscopy. Presence of cardiovascular comorbid conditions was associated with reduced odds of medical oncology referral (odds ratio, 0.65; 95% CI, 0.50 to 0.89). ConclusionIn these data, we observed no evidence of racial disparities in CRC care quality. Future studies could examine causal pathways for the VA's equal, quality care and ways to translate the VA's success into other hospital systems.

show abstract

Disparities in colorectal cancer in African-Americans vs Whites: Before and after diagnosis

Cited by 122 publications

References 91 publications

Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway

Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway

A Multi-institutional Study of Pancreatic Cancer in Harris County, Texas: Race Predicts Treatment and Survival

Examining Potential Colorectal Cancer Care Disparities in the Veterans Affairs Health Care System

Contact Info

Product

Resources

About